Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R_rs2016347 to predict tumor recurrence in estrogen receptor–positive breast cancer patients.
T. Winder
No relevant relationships to disclose
G. Giamas
No relevant relationships to disclose
W. Zhang
No relevant relationships to disclose
D. Yang
No relevant relationships to disclose
P. O. Bohanes
No relevant relationships to disclose
Y. Ning
No relevant relationships to disclose
A. Gerger
No relevant relationships to disclose
M. J. Labonte
No relevant relationships to disclose
J. Stebbing
No relevant relationships to disclose
H. Lenz
No relevant relationships to disclose